| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PALI | Common Stock, par value $0.01 | Award | $5,100 | +10,000 | +21% | $0.5100 | 57,781 | 20 Nov 2023 | Direct | F1 |
| holding | PALI | Common Stock, par value $0.01 | 777 | 20 Nov 2023 | By FCW Investments, LLC | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PALI | Restricted Stock Units | Award | $0 | +38,000 | $0.000000 | 38,000 | 21 Nov 2023 | Common Stock | 38,000 | Direct | F3, F4, F5, F6 | ||
| transaction | PALI | Common Stock Options | Award | $0 | +45,000 | $0.000000 | 45,000 | 21 Nov 2023 | Common Stock | 45,000 | $0.5900 | Direct | F3, F7, F8 |
| Id | Content |
|---|---|
| F1 | Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from July 1, 2023 through November 20, 2023. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on November 20, 2023. |
| F2 | Reporting Person is the managing member of FCW Investments LLC and has the sole investment and voting power over the securities held by this entity. |
| F3 | The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting. |
| F4 | Each restricted stock unit represents the right to receive, at settlement, one share of common stock. |
| F5 | The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. |
| F6 | N/A. |
| F7 | Each option represents the right to purchase one share of common stock at the exercise price. |
| F8 | The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date. |